



## **Morphic to Participate in Jefferies Global Healthcare Conference**

May 31, 2024

WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- [Morphic Therapeutic](#) (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5<sup>th</sup>, at 10:30 AM ET.

A live webcast of the panel discussion and fireside chat at the Jefferies Global Healthcare Conference will be available on the Investor section of Morphic's website at [www.morphictx.com](http://www.morphictx.com). An archived replay will be available on the company's website following the conference.

### **About Morphic Therapeutic**

Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company's unique understanding of integrin structure and biology. For more information, visit [www.morphictx.com](http://www.morphictx.com).

### **Contacts**

Morphic Therapeutic

Chris Erdman

[chris.erdman@morphictx.com](mailto:chris.erdman@morphictx.com)

617.686.1718